Quantify Research will be attending the World Evidence, Pricing and Access Congress in 📍Amsterdam, 📆 March 3–4.
Béranger Lueza, PhD & Abraham Choong will represent Quantify on site.
You will find us at Booth 302, together with our colleagues Pascale Holzerny, PhD, David Steinl, Susanne Bochat, and Ilda Theka, PhD, MBA from IGES Pharma, as part of the athagoras Group.
This year’s programme reflects a shifting access landscape:
➡️ Real-world evidence in pricing and reimbursement decisions
➡️ Implementation of Joint Clinical Assessment (JCA) under EU HTA
➡️ Developments around the US Most Favored Nation (MFN) policy and European implications
As a Nordic-focused RWE and HEOR partner, we are particularly attentive to how these developments translate into regional evidence requirements and access realities.
For market access teams, methodological credibility and strategic clarity are no longer optional. They are expected.
If you are attending, we would be pleased to exchange perspectives.
Will we see you at booth 302?
